Multiple preclinical studies have shown a high expression level of TROP2 in ovarian cancers, and preclinical data on the use of targeted treatments, such as sacituzumab govitecan and datopotamab deruxtecan, have shown fantastic responses in cases overexpressing TROP2 [71,87]. The gene discussed is TACSTD2; the disease is ovarian carcinoma.